Efficacy of induction therapy with high-dose interferon for patients with hemophilia and human immunodeficiency virus-hepatitis C virus coinfection

Clinical Infectious Diseases

Volumn 35, Issue 12, 2002, Pages 1527-1533

  Hanabusa, Hideji ^a  

^a Ogikubo Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; INTERFERON; RIBAVIRIN;

ADULT; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; LYMPHOCYTE COUNT; MYALGIA; NAUSEA; PATIENT SELECTION; PRIORITY JOURNAL; RASH; VIRUS LOAD;

ADULT; COHORT STUDIES; HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; INTERFERONS; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0037115310     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344755     Document Type: Article

References (30)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity, and mortality among patients with advanced human irnmunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14:949-53.
3. Hanabusa H. Progression of hepatitis C in hemophiliacs with HIV infection: Investigation on treatment with anti-HIV infection agents and IFN α [abstract 19]. In: Program and abstracts of the 9th Congress of the Japanese Society for AIDS Research (Osaka). Toyonaka, Japan: Japanese Society for AIDS Research, 1995:33.
4. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997;350:1425-31.
5. Seeff LB. Natural history of hepatitis C. Am J Med 1999; 107:S10-5.
6. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778-89.
7. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
8. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226-31.
9. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32:647-53.
10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
11. Fried MW, Shiffman M, Sterling RK, et al. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: Pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95:3225-9.
12. Kuboki M, Koide N, Kinoshita M, Ishida Y, Yamamoto S. Simultaneous determination of viral load and genotype of hepatitis C virus by direct sequencing of the product from the Amplicor HCV Monitor v2.0 test. Hepatology 2000; 32:277A.
13. Fukai K, Yokosuka O, Fujiwara K, et al. Etiologic considerations of fulminant non-A, non-B viral hepatitis in Japan: Analyses by nucleic acid amplification method. J Infect Dis 1998; 178:325-33.
14. Okamoto H, Nakao H, Inoue T, et al. The entire nucleotide sequences of two GB virus C/hepatitis G virus isolates of distinct genotypes from Japan. J Gen Virol 1997; 78:737-45.
15. Niro GA, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey JL. The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 1997;25:728-34.
16. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333: 450-1.
17. Harrington M, Carpenter CC. Hit HIV-1 hard, but only when necessary. Lancet 2000; 355:2147-52.
18. Bain VG. Effect of HCV viral dynamics on treatment design: Lessons learned from HIV. Am J Gastroenterol 2001; 96:2818-28.
19. Landau A, Batisse D, Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000; 14:839-44.
20. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-1.
21. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997;41:1231-6.
22. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001; 33:1299-302.
23. Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J Infect Dis 1999; 179:1062-9.
24. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
25. Takayama S, Miura T, Matsuo S, Taki M, Sugii S. Prevalence and persistence of a novel DNA TT virus (TTV) infection in Japanese haemophiliacs. Br J Haematol 1999; 104:626-9.
26. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341:22-6.
27. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-3.
28. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22(4 Pt 1):1050-6.
29. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175:164-8.
30. Daar ES, Lynn H, Donfield S, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001; 183:589-95.